
In a significant advancement for sleep and metabolic health, a new oral GLP-1 medication is poised to reshape the treatment landscape for obesity and its associated conditions, including obstructive sleep apnea (OSA). Eli Lilly's once-daily pill, orforglipron, is currently in advanced trials and has demonstrated promising results in both weight loss and blood sugar control. The true innovation lies in integrating these therapies into comprehensive care pathways—an initiative that Wesper is preparing to launch. From Injection to Innovation GLP-1 receptor agonists have revolutionized the management of type 2 diabetes and obesity, offering patients significant, sustainable weight loss and improved metabolic...
Featured Articles

When insomnia threatens your career, prioritizing...
READ
In choosing between home sleep tests...
READ
Sleep apnea can lead to dizziness...
READthe WESPER JOURNAL
Discover Our
Clinical Validations
Wesper’s technology is backed by rigorous clinical validations, ensuring accuracy and reliability in sleep health monitoring. Tested against gold-standard sleep studies, Wesper delivers precise data on sleep quality, stages, snoring, and breathing patterns, providing both patients and providers with trusted insights for effective sleep management.

GETTING TO KNOW OUR SLEEP EXPERT
Questions? Dr. Rohrscheib has Answers.
Struggling with undiagnosed sleep apnea? You’ve come to the right place. Dr. Chelsie Rohrscheib, our in-house sleep expert and researcher, provides valuable educational content on conditions associated with sleep apnea and how Wesper can offer solutions to help you take control of your sleep health.